Insider Transactions in Q1 2023 at Theravance Biopharma, Inc. (TBPH)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 14
2023
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Open market or private sale
|
Direct |
2,323
-0.62%
|
$23,230
$10.32 P/Share
|
|
Mar 09
2023
|
Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS |
SELL
Open market or private sale
|
Direct |
4,000
-1.1%
|
$40,000
$10.2 P/Share
|
|
Mar 06
2023
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Open market or private sale
|
Direct |
2,323
-0.62%
|
$23,230
$10.05 P/Share
|
|
Mar 01
2023
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
330,000
+16.72%
|
-
|
|
Mar 01
2023
|
Brett A. Grimaud SVP, GEN COUNSEL AND SECRETARY |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+19.74%
|
-
|
|
Mar 01
2023
|
Aziz Sawaf SVP & CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+22.36%
|
-
|
|
Mar 01
2023
|
Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+17.08%
|
-
|
|
Mar 01
2023
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+16.61%
|
-
|
|
Feb 26
2023
|
Susannah Gray |
BUY
Grant, award, or other acquisition
|
Direct |
11,819
+31.25%
|
-
|
|
Feb 20
2023
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
37,420
-2.77%
|
$374,200
$10.44 P/Share
|
|
Feb 20
2023
|
Aziz Sawaf SVP & CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
6,783
-3.32%
|
$67,830
$10.44 P/Share
|
|
Feb 20
2023
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Payment of exercise price or tax liability
|
Direct |
12,057
-3.85%
|
$120,570
$10.44 P/Share
|
|
Feb 20
2023
|
Brett A. Grimaud SVP, GEN COUNSEL AND SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
10,198
-4.25%
|
$101,980
$10.44 P/Share
|
|
Feb 20
2023
|
Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS |
SELL
Payment of exercise price or tax liability
|
Direct |
7,119
-2.4%
|
$71,190
$10.44 P/Share
|